{"gene":"KRAS","run_date":"2026-06-10T02:59:49","timeline":{"discoveries":[{"year":2018,"finding":"KRAS dimerization at the α4-α5 interface mediates wild-type KRAS-dependent growth inhibition of KRAS-mutant tumor cells and underlies resistance to MEK inhibition. The dimerization-defective mutant KRASD154Q abrogates these effects both in vitro and in vivo, establishing that dimerization is required for oncogenic KRAS activity.","method":"Genetically inducible KRAS LOH model, KRASD154Q dimer-interface mutant, in vitro and in vivo tumor growth assays, MEK inhibitor sensitivity assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal genetic and biochemical approaches, in vitro and in vivo validation, dimer-interface mutagenesis with multiple functional readouts","pmids":["29336889"],"is_preprint":false},{"year":2015,"finding":"GTP-bound K-Ras4B catalytic domain forms stable homodimers with two major dimer interfaces: a β-sheet interface overlapping switch I and effector-binding regions (inhibitory to effectors) and a helical interface that may promote Raf activation, suggesting Ras self-association regulates effector binding.","method":"Structural modeling, biophysical characterization of K-Ras4B GTP-bound catalytic domain dimerization","journal":"Structure","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — structural/biophysical analysis with functional inference, single lab, no in-cell validation in this study","pmids":["26051715"],"is_preprint":false},{"year":2018,"finding":"Full-length, natively processed K-Ras4B (with farnesylation and methylation) lacks intrinsic dimerization capability on supported lipid bilayer membranes across a wide range of surface densities and lipid compositions, suggesting any lateral organization in living cells requires additional factors.","method":"Fluorescence correlation spectroscopy and single-molecule tracking in supported lipid bilayer membranes","journal":"Biophysical journal","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — rigorous biophysical in vitro assay with native post-translational modifications, single lab, directly contradicts some dimerization claims","pmids":["29320680"],"is_preprint":false},{"year":2019,"finding":"KRAS G13D mutant is sensitive to neurofibromin (NF1)-stimulated GTP hydrolysis. Crystal structures of KRAS G13D in complex with the NF1 RasGAP domain provide the structural basis for this hydrolysis, and KRAS G13D-mutated cells can respond to EGFR inhibitors in a neurofibromin-dependent manner.","method":"In vitro GTP hydrolysis assay, crystal structure determination of KRAS G13D/neurofibromin complex, cell-based EGFR inhibitor response assays with NF1 dependency","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus in vitro biochemical assay plus cell-based functional validation, multiple orthogonal methods in one study","pmids":["31611389"],"is_preprint":false},{"year":2016,"finding":"Oncogenic mutations at G12, G13, and Q61 in K-Ras4B impair GAP-assisted GTP hydrolysis by disrupting the R789 arginine finger / Q61 catalytic organization. G12C/G12D mutations additionally expose the bound nucleotide in the GDP state, facilitating GDP-to-GTP exchange. The mutations differentially drive an inactive-to-active conformational transition in the GTP-bound state.","method":"Molecular dynamics simulations (6.4 μs total) on wild-type and mutant K-Ras4B with and without GAP","journal":"Scientific reports","confidence":"Low","confidence_rationale":"Tier 4 / Moderate — computational simulation only, no experimental validation in this study","pmids":["26902995"],"is_preprint":false},{"year":2000,"finding":"Crystal structures of four FTase ternary complexes with K-Ras4B peptide substrates reveal that the CAAX motif binds in extended conformation coordinating the active-site zinc ion, and the K-Ras4B polybasic region forms a type I β-turn along the rim of the hydrophobic cavity, providing the molecular basis for the high-affinity specificity of K-Ras4B for FTase.","method":"X-ray crystallography (2 Å resolution ternary complex structures)","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution crystal structures with multiple complexes providing direct structural basis for substrate specificity","pmids":["10673434"],"is_preprint":false},{"year":1995,"finding":"K-Ras4B processing (farnesylation) is highly resistant to FTI-277 (IC50 ~10 μM) but sensitive to the GGTase I inhibitor GGTI-286 (IC50 ~2 μM), demonstrating that K-Ras4B can undergo geranylgeranylation as an alternative prenylation when farnesylation is blocked, and that its oncogenic signaling (MAP kinase activation) is selectively disrupted by GGTase I inhibition.","method":"Cell-based prenylation processing assay, MAP kinase activation assay, CAAX peptidomimetic inhibitor treatment","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based biochemical assays with isoform-selective inhibitors, single lab, multiple functional readouts","pmids":["7592913"],"is_preprint":false},{"year":2009,"finding":"The C-terminal hypervariable region (HVR) of K-Ras4B is responsible for its specific interaction with calmodulin. The HVR binds specifically to the C-terminal domain of Ca2+-loaded calmodulin with micromolar affinity, while the GTP-γ-S-loaded catalytic domain may interact with the N-terminal domain of calmodulin, providing nucleotide-dependent control of the interaction.","method":"NMR spectroscopy and isothermal titration calorimetry","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — two orthogonal biophysical methods (NMR + ITC), domain-mapping experiments, single lab","pmids":["19583261"],"is_preprint":false},{"year":2010,"finding":"Calmodulin (CaM) inhibits K-Ras4B phosphorylation at Ser181 by PKC in vivo. PKC-mediated Ser181 phosphorylation decreases K-Ras4B susceptibility to p120GAP activity and is required for sustained ERK/AKT activation, cell proliferation, and oncogenic functions including focus formation and apoptosis resistance.","method":"Cell-based phosphorylation assays, non-phosphorylable K-Ras mutant (S181A), p120GAP activity assay, proliferation and focus formation assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — site-directed mutagenesis plus multiple cell-based functional assays, single lab","pmids":["20802526"],"is_preprint":false},{"year":2016,"finding":"Ca2+/calmodulin extracts K-Ras4B from negatively charged membranes in a nucleotide-independent manner, and the CaM/K-Ras4B complex does not bind membranes, demonstrating that CaM regulates K-Ras4B plasma membrane localization by sequestering it from the bilayer. This mechanism differs from PDEδ-mediated regulation.","method":"Fluorescence/FRET spectroscopy, FCS, and imaging in heterogeneous model biomembranes with GDP- and GTP-loaded K-Ras4B","journal":"Biophysical journal","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — multiple biophysical methods with model membranes, single lab, in vitro reconstitution","pmids":["27410739"],"is_preprint":false},{"year":2005,"finding":"K-Ras4B associates dynamically with the plasma membrane and undergoes rapidly reversible binding; using rapamycin-regulated heterodimerization, K-Ras4B or its targeting sequence alone can transfer from the plasma membrane to mitochondria within minutes, unlike multiply lipid-modified constructs anchored to the PM.","method":"Fluorescence microscopy, rapamycin-regulated protein heterodimerization, live cell imaging","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct live-cell imaging with rapamycin-regulated system, quantitative kinetics, single lab","pmids":["16236799"],"is_preprint":false},{"year":2019,"finding":"BI-2852 binds with nanomolar affinity to the switch I/II pocket between switch I and II of KRAS (present in both active and inactive forms), blocking all GEF, GAP, and effector interactions with KRAS simultaneously, leading to inhibition of downstream signaling and antiproliferative effects in KRAS mutant cells.","method":"Structure-based drug design, biochemical binding assay, GEF/GAP/effector interaction assays, cell proliferation assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure-guided design, multiple biochemical interaction assays demonstrating simultaneous blockade, cell-based functional validation","pmids":["31332011"],"is_preprint":false},{"year":2012,"finding":"KRAS is poorly translated relative to HRAS due to enrichment in rare codons. Converting rare to common codons increases KRas protein expression and tumorigenicity to mirror that of HRas, demonstrating that synonymous codon usage is a hardwired regulatory mechanism controlling KRas protein levels and oncogenic activity.","method":"Codon-optimized KRAS expression constructs, protein expression quantification, tumorigenicity assays","journal":"Current biology : CB","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct experimental manipulation of codon usage with functional readouts (protein level, tumorigenicity), single lab","pmids":["23246410"],"is_preprint":false},{"year":2018,"finding":"K-RAS4B localized to the plasma membrane via prenylation adopts an orientation in which the membrane occludes the effector-binding site when a small molecule (Cmpd2) simultaneously engages a shallow pocket on KRAS and associates with the lipid bilayer, thereby reducing RAF binding and impairing RAF activation.","method":"NMR spectroscopy of prenylated K-RAS4B in lipid bilayer, RAF binding assay, cell signaling assay","journal":"Cell chemical biology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — NMR structural analysis with lipid bilayer plus functional RAF binding assay, single lab","pmids":["30122370"],"is_preprint":false},{"year":2017,"finding":"Phosphorylation at Ser181 reduces K-Ras4B membrane binding affinity without fully preventing membrane binding or clustering, and phosphorylated K-Ras4B maintains tight association with its cytosolic shuttle protein PDEδ; cells receiving a non-hydrolyzable phosphoserine mimetic show decreased plasma membrane distribution compared to non-phosphorylable K-Ras4B.","method":"Chemically synthesized K-Ras4B bearing phosphate, farnesyl and methyl modifications, model biomembrane binding assays, cell microinjection","journal":"ACS chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — fully post-translationally modified protein reconstituted in vitro, multiple biophysical methods, cell-based validation with phosphoserine mimetic","pmids":["28448716"],"is_preprint":false},{"year":2010,"finding":"Recombinant K-Ras4B interacts with lipids and this interaction is mediated by its C-terminal hypervariable region, as demonstrated using phospholipid bilayer nanodiscs.","method":"Nanodisc reconstitution, NMR, protein purification","journal":"Protein expression and purification","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct biophysical reconstitution with nanodiscs, single lab, single method","pmids":["20566322"],"is_preprint":false},{"year":2001,"finding":"Wild-type Kras2 functions as a tumor suppressor in lung tumorigenesis: heterozygous Kras2-deficient mice show increased susceptibility to chemically-induced lung tumors, wild-type Kras2 inhibits colony formation and tumor development by cells with activated Kras2, and an inverse correlation exists between wild-type Kras2 expression and ERK activity.","method":"Mouse tumor bioassay with Kras2-deficient mice, colony formation assay, tumor xenograft, ERK activity measurement","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple in vivo and in vitro models, genetic and biochemical readouts, independently validated in human tumors","pmids":["11528387"],"is_preprint":false},{"year":2016,"finding":"Kras is the unique Ras family member required for B cell development: hematopoietic-specific deletion of Kras impairs early B cell development at the pre-B cell stage and late maturation, and Kras deficiency specifically impairs pre-BCR- and BCR-induced activation of the Raf-1/MEK/ERK pathway in pre-B and mature B cells.","method":"Conditional Kras knockout mice, bone marrow chimeras with B cell-specific Kras deletion, B cell development analysis, Raf-1/MEK/ERK pathway analysis","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional KO with multiple developmental stage readouts and pathway analysis, single lab but multiple orthogonal approaches","pmids":["26773157"],"is_preprint":false},{"year":2024,"finding":"KRAS-dependent transcription in KRAS-mutant cancers is driven predominantly through the ERK MAPK cascade. ERK deregulates the anaphase-promoting complex/cyclosome (APC/C) and other cell cycle machinery components as key processes driving PDAC growth, revealed by integration of KRAS/ERK-dependent transcriptome with ERK-regulated phospho- and total proteome.","method":"Genome-scale loss-of-function, RNA-seq, phosphoproteomics, total proteomics in KRAS-mutant cancer lines and patient data","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — multi-omic approach integrating transcriptomics and proteomics with direct genetic perturbation, validated in patient data","pmids":["38843331"],"is_preprint":false},{"year":2023,"finding":"Allosteric communication in KRAS propagates particularly effectively across the central β-sheet, and multiple surface pockets are genetically validated as allosterically active, including a distal pocket in the C-terminal lobe. Allosteric mutations typically inhibit binding to all tested effectors but can also change binding specificity, revealing potential to tune pathway activation.","method":"Deep mutational scanning of >26,000 KRAS mutations measuring effects on folding and binding to six interaction partners; genetic interaction analysis in double mutants to infer >22,000 causal free energy changes","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — large-scale quantitative biophysical measurements at protein scale with functional validation, multiple interaction partners tested","pmids":["38109937"],"is_preprint":false},{"year":2022,"finding":"Feedback reactivation of RAS-MAPK signaling upon KRASG12C inhibition is driven by upstream feedback activation of wild-type RAS (not by a shift of KRASG12C to GTP-bound state), and multiple receptor tyrosine kinases can drive this reactivation in a KRASG12C-independent manner.","method":"Biochemical assays distinguishing KRASG12C-GTP vs wild-type RAS-GTP, RTK perturbation experiments, cell signaling analysis in NSCLC and CRC models","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple mechanistic approaches distinguishing KRASG12C from wild-type RAS reactivation, single lab","pmids":["35732135"],"is_preprint":false},{"year":2015,"finding":"The disordered HVR of K-Ras4B undergoes auto-inhibition by shielding the effector binding site in the GDP-bound state, with release upon GTP binding or certain oncogenic mutations; oncogenic mutations G12V/G12D modulate HVR-phospholipid binding specificity toward preferential interactions with phosphatidic acid.","method":"NMR spectroscopy, phospholipid binding specificity experiments with oncogenic K-Ras4B mutants","journal":"Current opinion in structural biology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — NMR-based structural analysis with partial functional follow-up, single lab, some claims are proposed/model-based","pmids":["26709496"],"is_preprint":false},{"year":2025,"finding":"ASP3082, a KRASG12D-selective degrader, induces KRASG12D protein degradation via a lysosome-dependent (VHL-mediated) process with remarkable selectivity, as shown by a crystal structure of the drug-induced ternary complex KRASG12D/ASP3082/VHL, with tumor regression in KRASG12D xenografts.","method":"Crystal structure of ternary complex, in vitro degradation assay, xenograft tumor model","journal":"Communications chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure of ternary complex plus in vitro and in vivo functional validation, single lab, rigorous structural basis","pmids":["40849515"],"is_preprint":false},{"year":2024,"finding":"SRC kinase drives multidrug resistance to KRASG12C inhibition by activating the transcription factor JUN, which drives ABCC1 (multidrug transporter) expression. A genome-wide CRISPR screen identified ABCC1 as a resistance mediator, and SRC inhibitors (dasatinib, bosutinib) synergize with the KRASG12C inhibitor MRTX849 by blocking SRC-dependent JUN activation.","method":"Genome-wide CRISPR screen, JUN/ABCC1 pathway analysis, SRC inhibitor combination assays in cell lines, organoids, and mouse models","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 / Strong — unbiased genome-wide CRISPR screen followed by mechanistic pathway validation and in vivo confirmation, multiple model systems","pmids":["39661665"],"is_preprint":false},{"year":2012,"finding":"K-Ras4B forms dimers in vitro, observable with fully processed (farnesylated, methylated) protein preparations, suggesting dimerization could be important for activity and membrane interactions.","method":"In vitro biochemical characterization of purified K-Ras4B lipoprotein","journal":"Protein expression and purification","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single in vitro observation, single method, not functionally validated","pmids":["22569482"],"is_preprint":false},{"year":2023,"finding":"CAF-derived NRG1 activates cancer cell ERBB2 and ERBB3 receptor tyrosine kinases to support KRAS*-independent growth in PDAC. Genetic extinction or pharmacological inhibition of KRAS* upregulates ERBB2 and ERBB3 in cancer cells, prompting use of CAF-derived NRG1 as a survival factor; inhibition of ERBB2/3 or NRG1 abolished KRAS* bypass.","method":"Genetic depletion and pharmacological inhibition of KRAS*, ERBB2/3, and NRG1 in mouse and human PDAC models, co-culture experiments","journal":"Genes & development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological perturbations in multiple model systems, single lab, clear mechanistic pathway","pmids":["37775182"],"is_preprint":false}],"current_model":"KRAS encodes a membrane-associated small GTPase that cycles between inactive GDP-bound and active GTP-bound states regulated by GEFs and GAPs; oncogenic mutations (G12, G13, Q61) impair GAP-stimulated GTP hydrolysis (with G13D retaining neurofibromin-sensitivity), driving constitutive activation of RAF/MEK/ERK and PI3K/AKT downstream signaling; K-Ras4B requires farnesylation and polybasic HVR for plasma membrane localization, undergoes dynamic membrane association regulated by calmodulin (which extracts it from the membrane) and PDEδ, is phosphorylated at Ser181 by PKC (antagonized by CaM) to reduce GAP sensitivity and modulate signaling, and can dimerize via the α4-α5 interface in a manner that influences MEK inhibitor sensitivity and oncogenic activity; its rare codon enrichment limits protein expression compared to HRAS, and KRAS-driven transcription operates predominantly through ERK to deregulate the APC/C and cell cycle machinery."},"narrative":{"mechanistic_narrative":"KRAS encodes a membrane-associated small GTPase that cycles between inactive GDP-bound and active GTP-bound states to drive RAF/MEK/ERK signaling, with oncogenic activation occurring when mutations at G12, G13, and Q61 disrupt the GAP arginine finger/Q61 catalytic organization required for GTP hydrolysis [PMID:26902995]. The catalytic mutants are not uniformly GAP-insensitive: KRAS G13D retains susceptibility to neurofibromin (NF1)-stimulated hydrolysis, and KRAS G13D cells respond to EGFR inhibitors in an NF1-dependent manner [PMID:31611389]. Plasma membrane targeting of K-Ras4B depends on C-terminal processing — FTase recognizes the CAAX motif and adjacent polybasic region with high specificity [PMID:10673434], though the protein can be alternatively geranylgeranylated when farnesylation is blocked, with oncogenic MAP kinase signaling sensitive to GGTase I inhibition [PMID:7592913]. Membrane association is dynamic and reversible [PMID:16236799] and is governed by the hypervariable region, which mediates lipid binding [PMID:20566322], interacts with Ca2+-loaded calmodulin to extract K-Ras4B from the bilayer [PMID:19583261, PMID:27410739], and is phosphorylated at Ser181 by PKC (antagonized by calmodulin) to reduce p120GAP susceptibility, lower membrane affinity, and sustain ERK/AKT-driven proliferation and oncogenic function [PMID:20802526, PMID:28448716]. KRAS can self-associate through a dimer interface, and the dimerization-defective KRAS D154Q mutant abrogates oncogenic activity and MEK-inhibitor resistance, establishing dimerization as required for KRAS function [PMID:29336889]. Deep mutational scanning maps allosteric communication across the central β-sheet and identifies surface pockets that tune effector binding [PMID:38109937], and KRAS-dependent transcription in mutant cancers operates predominantly through ERK to deregulate the APC/C and cell cycle machinery driving PDAC growth [PMID:38843331]. Counterbalancing its oncogenic role, wild-type Kras2 acts as a tumor suppressor that restrains ERK activity and inhibits tumors driven by activated Kras [PMID:11528387], and Kras is uniquely required among Ras genes for pre-BCR/BCR-driven Raf-1/MEK/ERK signaling in B cell development [PMID:26773157]. KRAS is therapeutically targeted by switch I/II-pocket inhibitors [PMID:31332011], membrane-orientation-modulating compounds [PMID:30122370], and a KRAS G12D-selective VHL-recruiting degrader [PMID:40849515], but resistance arises through feedback reactivation of wild-type RAS via RTKs [PMID:35732135], SRC–JUN-driven ABCC1 expression [PMID:39661665], and CAF-derived NRG1 engagement of ERBB2/3 [PMID:37775182].","teleology":[{"year":1995,"claim":"Established how K-Ras4B reaches the membrane and whether its prenylation could be pharmacologically intercepted, revealing it escapes FTase inhibition via alternative geranylgeranylation.","evidence":"Cell-based prenylation and MAP kinase activation assays with isoform-selective CAAX inhibitors","pmids":["7592913"],"confidence":"Medium","gaps":["Does not establish in vivo relevance of GGTase I targeting in tumors","No structural basis for the differential inhibitor sensitivity"]},{"year":2000,"claim":"Defined the structural basis for K-Ras4B's high-affinity recognition by farnesyltransferase, explaining CAAX and polybasic-region specificity.","evidence":"X-ray crystallography of four FTase/K-Ras4B peptide ternary complexes at 2 Å","pmids":["10673434"],"confidence":"High","gaps":["Peptide substrates rather than full-length protein","Does not address alternative prenylation enzymes"]},{"year":2001,"claim":"Demonstrated that wild-type Kras paradoxically acts as a tumor suppressor restraining ERK, reframing the gene as dual-function rather than purely oncogenic.","evidence":"Kras2-deficient mouse lung tumor bioassays, colony formation, xenograft, and ERK activity measurement","pmids":["11528387"],"confidence":"High","gaps":["Molecular mechanism of WT suppression of mutant Kras not resolved here","Tissue specificity of the suppressor role unclear"]},{"year":2005,"claim":"Showed that K-Ras4B membrane binding is rapidly reversible rather than static, establishing dynamic membrane shuttling as a regulatory feature.","evidence":"Rapamycin-regulated heterodimerization and live-cell imaging of PM-to-mitochondria transfer","pmids":["16236799"],"confidence":"Medium","gaps":["Physiological trigger for membrane release not defined","Single-cell imaging without endogenous-level confirmation"]},{"year":2009,"claim":"Identified calmodulin as a nucleotide-sensitive HVR-binding partner, providing a molecular handle for K-Ras4B regulation beyond GEFs/GAPs.","evidence":"NMR and ITC domain-mapping of HVR/calmodulin interaction","pmids":["19583261"],"confidence":"High","gaps":["Cellular consequence of binding not tested in this study","Affinity measured on isolated domains"]},{"year":2010,"claim":"Connected PKC-mediated Ser181 phosphorylation (CaM-antagonized) to reduced GAP sensitivity and oncogenic output, defining a phospho-switch on the HVR.","evidence":"Cell-based phosphorylation and S181A mutant assays, p120GAP activity, proliferation and focus formation","pmids":["20802526"],"confidence":"Medium","gaps":["Quantitative stoichiometry of phosphorylation in tumors unknown","Direct structural effect on GAP binding not shown"]},{"year":2010,"claim":"Confirmed that the HVR is the lipid-binding determinant, grounding membrane targeting in a defined region.","evidence":"Nanodisc reconstitution and NMR of recombinant K-Ras4B","pmids":["20566322"],"confidence":"Medium","gaps":["Single method, no in-cell validation","Lipid composition dependence not explored"]},{"year":2012,"claim":"Revealed that synonymous rare-codon usage hardwires low KRAS protein levels, explaining the expression and tumorigenicity gap versus HRAS.","evidence":"Codon-optimized KRAS constructs with protein-level and tumorigenicity readouts","pmids":["23246410"],"confidence":"Medium","gaps":["Translational mechanism (tRNA availability vs elongation) not dissected","Relevance to endogenous regulation in normal tissue unclear"]},{"year":2015,"claim":"Proposed nucleotide-gated self-association with distinct dimer interfaces controlling effector access, opening the question of whether KRAS dimerizes functionally.","evidence":"Structural modeling and biophysical characterization of GTP-bound K-Ras4B catalytic domain","pmids":["26051715"],"confidence":"Medium","gaps":["No in-cell validation in this study","Catalytic domain only, lacks membrane context"]},{"year":2016,"claim":"Provided an atomistic account of how G12/G13/Q61 mutations impair GAP-assisted hydrolysis and bias the active conformation.","evidence":"Microsecond molecular dynamics simulations of wild-type and mutant K-Ras4B ± GAP","pmids":["26902995"],"confidence":"Low","gaps":["Computational only, no experimental validation in this study","Does not capture full-length membrane-bound dynamics"]},{"year":2016,"claim":"Showed calmodulin physically extracts K-Ras4B from membranes nucleotide-independently, defining a sequestration mechanism distinct from PDEδ.","evidence":"FRET/FCS/imaging in model biomembranes with GDP/GTP-loaded K-Ras4B","pmids":["27410739"],"confidence":"Medium","gaps":["In vitro model membranes only","Quantitative contribution to cellular PM pool not established"]},{"year":2016,"claim":"Established a unique, non-redundant requirement for Kras in B cell development via pre-BCR/BCR-driven MAPK signaling.","evidence":"Conditional Kras knockout mice and bone marrow chimeras with developmental and pathway analysis","pmids":["26773157"],"confidence":"High","gaps":["Why other Ras genes cannot compensate is unresolved","Direct receptor-to-Kras coupling not biochemically mapped"]},{"year":2017,"claim":"Demonstrated with fully modified protein that Ser181 phosphorylation lowers membrane affinity while preserving PDEδ binding, integrating phospho-regulation with the shuttle machinery.","evidence":"Chemically synthesized phospho/farnesyl/methyl K-Ras4B, model membrane assays, cell microinjection","pmids":["28448716"],"confidence":"High","gaps":["Downstream signaling consequences not quantified here","Endogenous phosphorylation dynamics not measured"]},{"year":2018,"claim":"Provided in vivo genetic proof that dimerization (D154Q-sensitive) is required for oncogenic KRAS activity and MEK-inhibitor resistance.","evidence":"Inducible KRAS LOH model, D154Q dimer-interface mutant, in vitro and in vivo tumor and MEKi assays","pmids":["29336889"],"confidence":"High","gaps":["Stoichiometry and partner of dimerization in cells not fully defined","Apparent tension with native-protein in vitro non-dimerization findings"]},{"year":2018,"claim":"Rigorously tested intrinsic dimerization of natively processed K-Ras4B and found none on bilayers, implying cellular clustering needs accessory factors.","evidence":"FCS and single-molecule tracking of farnesylated/methylated K-Ras4B on supported lipid bilayers","pmids":["29320680"],"confidence":"Medium","gaps":["Does not exclude dimerization driven by cellular factors","Single in vitro system"]},{"year":2018,"claim":"Showed that membrane orientation can occlude the effector site, identifying a druggable mode where a compound pins KRAS to the bilayer to block RAF.","evidence":"NMR of prenylated K-RAS4B in lipid bilayer plus RAF binding and signaling assays","pmids":["30122370"],"confidence":"Medium","gaps":["Single compound, single lab","In-cell potency and selectivity limited"]},{"year":2019,"claim":"Resolved that KRAS G13D remains neurofibromin-sensitive, structurally and functionally rationalizing EGFR-inhibitor responsiveness for this allele.","evidence":"In vitro hydrolysis, KRAS G13D/NF1 crystal structure, NF1-dependent EGFR inhibitor cell assays","pmids":["31611389"],"confidence":"High","gaps":["Generalizability to other codon-13 alleles untested","NF1 status dependence in patients not addressed"]},{"year":2019,"claim":"Validated the switch I/II pocket as a druggable site whose occupancy simultaneously blocks GEF, GAP, and effector engagement.","evidence":"Structure-based design of BI-2852 with binding, interaction-blockade, and proliferation assays","pmids":["31332011"],"confidence":"High","gaps":["Potency insufficient for clinical use","Mutant selectivity not achieved"]},{"year":2022,"claim":"Distinguished the source of adaptive resistance to KRASG12C inhibition as feedback activation of wild-type RAS via RTKs rather than re-loading of mutant KRAS.","evidence":"Biochemical KRASG12C-GTP vs WT-RAS-GTP discrimination and RTK perturbation in NSCLC/CRC models","pmids":["35732135"],"confidence":"Medium","gaps":["Identity of dominant upstream RTK varies by context","Single lab"]},{"year":2023,"claim":"Mapped genome-wide allosteric architecture of KRAS, identifying β-sheet-propagated communication and distal pockets that tune effector specificity.","evidence":"Deep mutational scanning of >26,000 variants against six partners with double-mutant free-energy inference","pmids":["38109937"],"confidence":"High","gaps":["Druggability of identified distal pockets not demonstrated","Performed outside full membrane context"]},{"year":2023,"claim":"Identified a stromal bypass route in which CAF-derived NRG1 sustains KRAS-independent growth through ERBB2/3 upon KRAS extinction.","evidence":"Genetic/pharmacological KRAS, ERBB2/3, NRG1 perturbation and co-culture in PDAC models","pmids":["37775182"],"confidence":"Medium","gaps":["Contribution relative to cell-intrinsic resistance unquantified","Single lab"]},{"year":2024,"claim":"Showed KRAS-mutant transcriptional output runs predominantly through ERK to deregulate the APC/C and cell cycle, defining the proliferative effector program.","evidence":"Genome-scale loss-of-function with integrated RNA-seq, phospho- and total proteomics in KRAS-mutant lines and patient data","pmids":["38843331"],"confidence":"High","gaps":["Direct transcription factors linking ERK to APC/C not all defined","Tissue scope beyond PDAC partial"]},{"year":2024,"claim":"Defined an SRC–JUN–ABCC1 axis driving multidrug resistance to KRASG12C inhibition and a synergistic SRC-inhibitor combination strategy.","evidence":"Genome-wide CRISPR screen with pathway validation and SRC-inhibitor combinations across cells, organoids, and mice","pmids":["39661665"],"confidence":"High","gaps":["Clinical translatability of the combination untested here","Whether axis generalizes to other KRAS alleles unknown"]},{"year":2025,"claim":"Delivered targeted KRASG12D protein degradation via a VHL-recruiting degrader, expanding KRAS therapeutics from inhibition to mutant-selective destruction.","evidence":"Ternary KRASG12D/ASP3082/VHL crystal structure, in vitro degradation, and xenograft regression","pmids":["40849515"],"confidence":"High","gaps":["Resistance mechanisms to degradation not yet characterized","Single lab"]},{"year":null,"claim":"How the in vitro non-dimerizing behavior of natively processed K-Ras4B is reconciled with the genetic requirement for dimerization in cells — i.e., what cellular factors organize KRAS lateral assembly — remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Accessory factors driving cellular dimerization unidentified","Structural model of the cellular dimer in a membrane context missing","Quantitative link between dimerization and effector activation incomplete"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003924","term_label":"GTPase activity","supporting_discovery_ids":[3,4]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[18]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[15,21]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[4,18]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[10,13,14]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[9,14]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[18,20]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[23,25]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[18]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[17]}],"complexes":[],"partners":["NF1","CALM1","PDE6D","RAF1","PRKC","VHL"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P01116","full_name":"GTPase KRas","aliases":["K-Ras 2","Ki-Ras","c-K-ras","c-Ki-ras"],"length_aa":189,"mass_kda":21.7,"function":"Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:20949621, PubMed:39809765). Plays an important role in the regulation of cell proliferation (PubMed:22711838, PubMed:23698361). Activates MAPK1/MAPK3 resulting in phosphorylation and ultimately degradation of GJA1 (By similarity). Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner (PubMed:24623306)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P01116/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/KRAS","classification":"Common Essential","n_dependent_lines":696,"n_total_lines":1208,"dependency_fraction":0.5761589403973509},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000133703","cell_line_id":"CID000479","localizations":[{"compartment":"membrane","grade":3},{"compartment":"cytoplasmic","grade":1}],"interactors":[{"gene":"YWHAH","stoichiometry":10.0},{"gene":"YWHAQ","stoichiometry":10.0},{"gene":"YWHAB","stoichiometry":10.0},{"gene":"YWHAG","stoichiometry":4.0},{"gene":"ACTR2","stoichiometry":4.0},{"gene":"YWHAZ","stoichiometry":0.2},{"gene":"YWHAE","stoichiometry":0.2},{"gene":"KIAA0430","stoichiometry":0.2},{"gene":"APPL1","stoichiometry":0.2},{"gene":"TRAPPC4","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID000479","total_profiled":1310},"omim":[{"mim_id":"621467","title":"NCBP2 ANTISENSE RNA 2 (HEAD TO HEAD); NCBP2AS2","url":"https://www.omim.org/entry/621467"},{"mim_id":"621092","title":"IQ MOTIF-CONTAINING GTPase-ACTIVATING PROTEIN 3; IQGAP3","url":"https://www.omim.org/entry/621092"},{"mim_id":"620654","title":"THROMBOCYTOPENIA 11 WITH MULTIPLE CONGENITAL ANOMALIES AND DYSMORPHIC FACIES; THC11","url":"https://www.omim.org/entry/620654"},{"mim_id":"620302","title":"WD REPEAT-CONTAINING PROTEIN 76; WDR76","url":"https://www.omim.org/entry/620302"},{"mim_id":"618712","title":"ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 45; ANKRD45","url":"https://www.omim.org/entry/618712"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/KRAS"},"hgnc":{"alias_symbol":["KRAS1","K-Ras4B"],"prev_symbol":["KRAS2"]},"alphafold":{"accession":"P01116","domains":[{"cath_id":"3.40.50.300","chopping":"1-175","consensus_level":"high","plddt":95.1591,"start":1,"end":175}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P01116","model_url":"https://alphafold.ebi.ac.uk/files/AF-P01116-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P01116-F1-predicted_aligned_error_v6.png","plddt_mean":91.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=KRAS","jax_strain_url":"https://www.jax.org/strain/search?query=KRAS"},"sequence":{"accession":"P01116","fasta_url":"https://rest.uniprot.org/uniprotkb/P01116.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P01116/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P01116"}},"corpus_meta":[{"pmid":"34776511","id":"PMC_34776511","title":"KRAS mutation: from undruggable to druggable in cancer.","date":"2021","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34776511","citation_count":831,"is_preprint":false},{"pmid":"24388967","id":"PMC_24388967","title":"KRAS: feeding pancreatic cancer proliferation.","date":"2014","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24388967","citation_count":566,"is_preprint":false},{"pmid":"29364867","id":"PMC_29364867","title":"Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.","date":"2018","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/29364867","citation_count":336,"is_preprint":false},{"pmid":"31332011","id":"PMC_31332011","title":"Drugging an undruggable pocket on KRAS.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31332011","citation_count":336,"is_preprint":false},{"pmid":"15608639","id":"PMC_15608639","title":"An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis.","date":"2004","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15608639","citation_count":336,"is_preprint":false},{"pmid":"28958387","id":"PMC_28958387","title":"KRAS Alleles: The Devil Is in the Detail.","date":"2017","source":"Trends in cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28958387","citation_count":294,"is_preprint":false},{"pmid":"20617134","id":"PMC_20617134","title":"Clinical relevance of KRAS in human cancers.","date":"2010","source":"Journal of biomedicine & biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/20617134","citation_count":294,"is_preprint":false},{"pmid":"33676749","id":"PMC_33676749","title":"KRAS mutation in pancreatic cancer.","date":"2021","source":"Seminars in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33676749","citation_count":286,"is_preprint":false},{"pmid":"31649840","id":"PMC_31649840","title":"Targeting the untargetable KRAS in cancer therapy.","date":"2019","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/31649840","citation_count":273,"is_preprint":false},{"pmid":"35046095","id":"PMC_35046095","title":"Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.","date":"2022","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35046095","citation_count":260,"is_preprint":false},{"pmid":"25878360","id":"PMC_25878360","title":"KRAS as a Therapeutic Target.","date":"2015","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/25878360","citation_count":258,"is_preprint":false},{"pmid":"11528387","id":"PMC_11528387","title":"Wildtype Kras2 can inhibit lung carcinogenesis in mice.","date":"2001","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11528387","citation_count":258,"is_preprint":false},{"pmid":"38637634","id":"PMC_38637634","title":"Targeting KRAS in cancer.","date":"2024","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38637634","citation_count":236,"is_preprint":false},{"pmid":"32711246","id":"PMC_32711246","title":"KRAS: From undruggable to a druggable Cancer Target.","date":"2020","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/32711246","citation_count":215,"is_preprint":false},{"pmid":"29336889","id":"PMC_29336889","title":"KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.","date":"2018","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/29336889","citation_count":213,"is_preprint":false},{"pmid":"23401440","id":"PMC_23401440","title":"KRAS mutation: should we test for it, and does it matter?","date":"2013","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23401440","citation_count":202,"is_preprint":false},{"pmid":"23122493","id":"PMC_23122493","title":"KRAS mutations in lung cancer.","date":"2012","source":"Clinical lung cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23122493","citation_count":187,"is_preprint":false},{"pmid":"26902995","id":"PMC_26902995","title":"The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26902995","citation_count":183,"is_preprint":false},{"pmid":"26051715","id":"PMC_26051715","title":"GTP-Dependent K-Ras Dimerization.","date":"2015","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/26051715","citation_count":176,"is_preprint":false},{"pmid":"23066310","id":"PMC_23066310","title":"KRAS mutation testing in metastatic colorectal cancer.","date":"2012","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/23066310","citation_count":171,"is_preprint":false},{"pmid":"7592913","id":"PMC_7592913","title":"Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7592913","citation_count":168,"is_preprint":false},{"pmid":"34471232","id":"PMC_34471232","title":"The KRAS-G12C inhibitor: activity and resistance.","date":"2021","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34471232","citation_count":162,"is_preprint":false},{"pmid":"27595930","id":"PMC_27595930","title":"KRAS-related proteins in pancreatic cancer.","date":"2016","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/27595930","citation_count":155,"is_preprint":false},{"pmid":"35732135","id":"PMC_35732135","title":"KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35732135","citation_count":137,"is_preprint":false},{"pmid":"29444439","id":"PMC_29444439","title":"Differential Effector Engagement by Oncogenic KRAS.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29444439","citation_count":122,"is_preprint":false},{"pmid":"23246410","id":"PMC_23246410","title":"Rare codons regulate KRas oncogenesis.","date":"2012","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/23246410","citation_count":118,"is_preprint":false},{"pmid":"10673434","id":"PMC_10673434","title":"The basis for K-Ras4B binding specificity to protein farnesyltransferase revealed by 2 A resolution ternary complex structures.","date":"2000","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/10673434","citation_count":112,"is_preprint":false},{"pmid":"31611389","id":"PMC_31611389","title":"KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31611389","citation_count":106,"is_preprint":false},{"pmid":"38109937","id":"PMC_38109937","title":"The energetic and allosteric landscape for KRAS inhibition.","date":"2023","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/38109937","citation_count":104,"is_preprint":false},{"pmid":"20857619","id":"PMC_20857619","title":"EGFR and KRAS in colorectal cancer.","date":"2010","source":"Advances in clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20857619","citation_count":101,"is_preprint":false},{"pmid":"38843331","id":"PMC_38843331","title":"Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers.","date":"2024","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/38843331","citation_count":94,"is_preprint":false},{"pmid":"35245687","id":"PMC_35245687","title":"Extrinsic KRAS Signaling Shapes the Pancreatic Microenvironment Through Fibroblast Reprogramming.","date":"2022","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/35245687","citation_count":80,"is_preprint":false},{"pmid":"30122370","id":"PMC_30122370","title":"Inhibition of K-RAS4B by a Unique Mechanism of Action: Stabilizing Membrane-Dependent Occlusion of the Effector-Binding Site.","date":"2018","source":"Cell chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/30122370","citation_count":78,"is_preprint":false},{"pmid":"16236799","id":"PMC_16236799","title":"K-ras4B and prenylated proteins lacking \"second signals\" associate dynamically with cellular membranes.","date":"2005","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/16236799","citation_count":75,"is_preprint":false},{"pmid":"34830757","id":"PMC_34830757","title":"Oncogenic KRAS: Signaling and Drug Resistance.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34830757","citation_count":73,"is_preprint":false},{"pmid":"28462395","id":"PMC_28462395","title":"Calmodulin and PI3K Signaling in KRAS Cancers.","date":"2017","source":"Trends in cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28462395","citation_count":69,"is_preprint":false},{"pmid":"34607583","id":"PMC_34607583","title":"Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.","date":"2021","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34607583","citation_count":66,"is_preprint":false},{"pmid":"38666907","id":"PMC_38666907","title":"Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer.","date":"2024","source":"Current issues in molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/38666907","citation_count":63,"is_preprint":false},{"pmid":"29320680","id":"PMC_29320680","title":"K-Ras4B Remains Monomeric on Membranes over a Wide Range of Surface Densities and Lipid Compositions.","date":"2018","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/29320680","citation_count":63,"is_preprint":false},{"pmid":"30711927","id":"PMC_30711927","title":"The Role of KRAS in Endometrial Cancer: A Mini-Review.","date":"2019","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30711927","citation_count":59,"is_preprint":false},{"pmid":"20802526","id":"PMC_20802526","title":"K-Ras4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-Ras activity and function.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20802526","citation_count":59,"is_preprint":false},{"pmid":"38686056","id":"PMC_38686056","title":"Targeting KRAS in pancreatic cancer.","date":"2024","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/38686056","citation_count":58,"is_preprint":false},{"pmid":"30971271","id":"PMC_30971271","title":"Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy.","date":"2019","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30971271","citation_count":58,"is_preprint":false},{"pmid":"33777798","id":"PMC_33777798","title":"Targeting KRAS: The Elephant in the Room of Epithelial Cancers.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33777798","citation_count":57,"is_preprint":false},{"pmid":"19583261","id":"PMC_19583261","title":"The hypervariable region of K-Ras4B is responsible for its specific interactions with calmodulin.","date":"2009","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19583261","citation_count":57,"is_preprint":false},{"pmid":"33995590","id":"PMC_33995590","title":"KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas.","date":"2021","source":"Therapeutic advances in medical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33995590","citation_count":52,"is_preprint":false},{"pmid":"39799325","id":"PMC_39799325","title":"Targeting KRAS: from metabolic regulation to cancer treatment.","date":"2025","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/39799325","citation_count":50,"is_preprint":false},{"pmid":"29440633","id":"PMC_29440633","title":"KRAS induces lung tumorigenesis through microRNAs modulation.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29440633","citation_count":50,"is_preprint":false},{"pmid":"36414681","id":"PMC_36414681","title":"Glimmers of hope for targeting oncogenic KRAS-G12D.","date":"2022","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/36414681","citation_count":49,"is_preprint":false},{"pmid":"28597297","id":"PMC_28597297","title":"Intrinsic protein disorder in oncogenic KRAS signaling.","date":"2017","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/28597297","citation_count":49,"is_preprint":false},{"pmid":"34303932","id":"PMC_34303932","title":"Stopping the beating heart of cancer: KRAS reviewed.","date":"2021","source":"Current opinion in structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/34303932","citation_count":49,"is_preprint":false},{"pmid":"29120102","id":"PMC_29120102","title":"Deciphering lipid codes: K-Ras as a paradigm.","date":"2017","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/29120102","citation_count":48,"is_preprint":false},{"pmid":"35014625","id":"PMC_35014625","title":"Targeting the undruggable oncogenic KRAS: the dawn of hope.","date":"2022","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/35014625","citation_count":47,"is_preprint":false},{"pmid":"19854534","id":"PMC_19854534","title":"KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer.","date":"2009","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/19854534","citation_count":47,"is_preprint":false},{"pmid":"29894909","id":"PMC_29894909","title":"KRAS: Reasons for optimism in lung cancer.","date":"2018","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/29894909","citation_count":45,"is_preprint":false},{"pmid":"27410739","id":"PMC_27410739","title":"Regulation of K-Ras4B Membrane Binding by Calmodulin.","date":"2016","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/27410739","citation_count":43,"is_preprint":false},{"pmid":"12606951","id":"PMC_12606951","title":"LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12606951","citation_count":42,"is_preprint":false},{"pmid":"35412860","id":"PMC_35412860","title":"Overcoming KRAS-Mutant Lung Cancer.","date":"2022","source":"American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting","url":"https://pubmed.ncbi.nlm.nih.gov/35412860","citation_count":41,"is_preprint":false},{"pmid":"26709496","id":"PMC_26709496","title":"The disordered hypervariable region and the folded catalytic domain of oncogenic K-Ras4B partner in phospholipid binding.","date":"2015","source":"Current opinion in structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/26709496","citation_count":41,"is_preprint":false},{"pmid":"35561303","id":"PMC_35561303","title":"More to the RAS Story: KRASG12C Inhibition, Resistance Mechanisms, and Moving Beyond KRASG12C.","date":"2022","source":"American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting","url":"https://pubmed.ncbi.nlm.nih.gov/35561303","citation_count":40,"is_preprint":false},{"pmid":"39047616","id":"PMC_39047616","title":"The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?","date":"2024","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/39047616","citation_count":39,"is_preprint":false},{"pmid":"35456940","id":"PMC_35456940","title":"KRAS: A Druggable Target in Colon Cancer Patients.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35456940","citation_count":39,"is_preprint":false},{"pmid":"34064352","id":"PMC_34064352","title":"Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors.","date":"2021","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/34064352","citation_count":38,"is_preprint":false},{"pmid":"37190303","id":"PMC_37190303","title":"The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/37190303","citation_count":37,"is_preprint":false},{"pmid":"38668053","id":"PMC_38668053","title":"KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance.","date":"2024","source":"Current oncology (Toronto, Ont.)","url":"https://pubmed.ncbi.nlm.nih.gov/38668053","citation_count":36,"is_preprint":false},{"pmid":"8661122","id":"PMC_8661122","title":"Coamplification in tumors of KRAS2, type 2 inositol 1,4,5 triphosphate receptor gene, and a novel human gene, KRAG.","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8661122","citation_count":35,"is_preprint":false},{"pmid":"39638567","id":"PMC_39638567","title":"\"Undruggable KRAS\": druggable after all.","date":"2025","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/39638567","citation_count":33,"is_preprint":false},{"pmid":"28448716","id":"PMC_28448716","title":"Phosphorylation Weakens but Does Not Inhibit Membrane Binding and Clustering of K-Ras4B.","date":"2017","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/28448716","citation_count":33,"is_preprint":false},{"pmid":"32796566","id":"PMC_32796566","title":"Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?","date":"2020","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/32796566","citation_count":30,"is_preprint":false},{"pmid":"34520956","id":"PMC_34520956","title":"Targeting mutated GTPase KRAS in tumor therapies.","date":"2021","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34520956","citation_count":29,"is_preprint":false},{"pmid":"26873344","id":"PMC_26873344","title":"K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?","date":"2016","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/26873344","citation_count":28,"is_preprint":false},{"pmid":"33582927","id":"PMC_33582927","title":"Targeting KRAS in Colorectal Cancer.","date":"2021","source":"Current oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/33582927","citation_count":27,"is_preprint":false},{"pmid":"39167893","id":"PMC_39167893","title":"Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers.","date":"2024","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39167893","citation_count":27,"is_preprint":false},{"pmid":"38937452","id":"PMC_38937452","title":"A pan-KRAS degrader for the treatment of KRAS-mutant cancers.","date":"2024","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/38937452","citation_count":25,"is_preprint":false},{"pmid":"24534449","id":"PMC_24534449","title":"KRAS mutations: analytical considerations.","date":"2014","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24534449","citation_count":25,"is_preprint":false},{"pmid":"35093302","id":"PMC_35093302","title":"Interplay between K-RAS and miRNAs.","date":"2022","source":"Trends in cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35093302","citation_count":24,"is_preprint":false},{"pmid":"26773157","id":"PMC_26773157","title":"Kras Is Critical for B Cell Lymphopoiesis.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26773157","citation_count":24,"is_preprint":false},{"pmid":"36977195","id":"PMC_36977195","title":"KRAS mutations and endometriosis burden of disease.","date":"2023","source":"The journal of pathology. Clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/36977195","citation_count":23,"is_preprint":false},{"pmid":"40849515","id":"PMC_40849515","title":"Discovery of KRAS(G12D) selective degrader ASP3082.","date":"2025","source":"Communications chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/40849515","citation_count":22,"is_preprint":false},{"pmid":"37696812","id":"PMC_37696812","title":"CBX4 deletion promotes tumorigenesis under KrasG12D background by inducing genomic instability.","date":"2023","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37696812","citation_count":22,"is_preprint":false},{"pmid":"34040167","id":"PMC_34040167","title":"AMPKα loss promotes KRAS-mediated lung tumorigenesis.","date":"2021","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/34040167","citation_count":22,"is_preprint":false},{"pmid":"29499269","id":"PMC_29499269","title":"Oncogenic KRas mobility in the membrane and signaling response.","date":"2018","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/29499269","citation_count":22,"is_preprint":false},{"pmid":"37775182","id":"PMC_37775182","title":"Stromal-derived NRG1 enables oncogenic KRAS bypass in pancreas cancer.","date":"2023","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/37775182","citation_count":22,"is_preprint":false},{"pmid":"36946612","id":"PMC_36946612","title":"KRAS Hijacks the miRNA Regulatory Pathway in Cancer.","date":"2023","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/36946612","citation_count":22,"is_preprint":false},{"pmid":"33838397","id":"PMC_33838397","title":"Targeting mutant KRAS.","date":"2021","source":"Current opinion in chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/33838397","citation_count":21,"is_preprint":false},{"pmid":"36321791","id":"PMC_36321791","title":"Realgar‑induced KRAS mutation lung cancer cell death via KRAS/Raf/MAPK mediates ferroptosis.","date":"2022","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36321791","citation_count":21,"is_preprint":false},{"pmid":"30976068","id":"PMC_30976068","title":"Detection of KRAS mutation via ligation-initiated LAMP reaction.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30976068","citation_count":21,"is_preprint":false},{"pmid":"20232877","id":"PMC_20232877","title":"Imaging human pancreatic cancer xenografts by targeting mutant KRAS2 mRNA with [(111)In]DOTA(n)-poly(diamidopropanoyl)(m)-KRAS2 PNA-D(Cys-Ser-Lys-Cys) nanoparticles.","date":"2010","source":"Bioconjugate chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20232877","citation_count":21,"is_preprint":false},{"pmid":"31277422","id":"PMC_31277422","title":"Activating Mutations in PTPN11 and KRAS in Canine Histiocytic Sarcomas.","date":"2019","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/31277422","citation_count":21,"is_preprint":false},{"pmid":"34898002","id":"PMC_34898002","title":"KRAS signaling in malignant pleural mesothelioma.","date":"2021","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34898002","citation_count":20,"is_preprint":false},{"pmid":"37524642","id":"PMC_37524642","title":"Immune vulnerabilities of mutant KRAS in pancreatic cancer.","date":"2023","source":"Trends in cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37524642","citation_count":20,"is_preprint":false},{"pmid":"34558391","id":"PMC_34558391","title":"KRAS G12C fragment screening renders new binding pockets.","date":"2021","source":"Small GTPases","url":"https://pubmed.ncbi.nlm.nih.gov/34558391","citation_count":20,"is_preprint":false},{"pmid":"31327761","id":"PMC_31327761","title":"miR-548d-3p inhibits osteosarcoma by downregulating KRAS.","date":"2019","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/31327761","citation_count":20,"is_preprint":false},{"pmid":"39661665","id":"PMC_39661665","title":"SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition.","date":"2024","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/39661665","citation_count":19,"is_preprint":false},{"pmid":"25244542","id":"PMC_25244542","title":"KRAS and BRAF mutations in anal carcinoma.","date":"2014","source":"APMIS : acta pathologica, microbiologica, et immunologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/25244542","citation_count":19,"is_preprint":false},{"pmid":"22569482","id":"PMC_22569482","title":"K-Ras4B lipoprotein synthesis: biochemical characterization, functional properties, and dimer formation.","date":"2012","source":"Protein expression and purification","url":"https://pubmed.ncbi.nlm.nih.gov/22569482","citation_count":18,"is_preprint":false},{"pmid":"31576556","id":"PMC_31576556","title":"Oncogenic BRAF and KRAS mutations in endosalpingiosis.","date":"2019","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31576556","citation_count":18,"is_preprint":false},{"pmid":"20566322","id":"PMC_20566322","title":"Expression, purification, and characterization of soluble K-Ras4B for structural analysis.","date":"2010","source":"Protein expression and purification","url":"https://pubmed.ncbi.nlm.nih.gov/20566322","citation_count":18,"is_preprint":false},{"pmid":"34680229","id":"PMC_34680229","title":"Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34680229","citation_count":17,"is_preprint":false},{"pmid":"37268395","id":"PMC_37268395","title":"Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies.","date":"2023","source":"Advances in cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/37268395","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":42317,"output_tokens":6160,"usd":0.109675,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":30088,"output_tokens":12844,"usd":0.352998,"resynth_parse_fail":true,"stage2_stop_reason":"end_turn"},"total_usd":0.462673,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2018,\n      \"finding\": \"KRAS dimerization at the α4-α5 interface mediates wild-type KRAS-dependent growth inhibition of KRAS-mutant tumor cells and underlies resistance to MEK inhibition. The dimerization-defective mutant KRASD154Q abrogates these effects both in vitro and in vivo, establishing that dimerization is required for oncogenic KRAS activity.\",\n      \"method\": \"Genetically inducible KRAS LOH model, KRASD154Q dimer-interface mutant, in vitro and in vivo tumor growth assays, MEK inhibitor sensitivity assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal genetic and biochemical approaches, in vitro and in vivo validation, dimer-interface mutagenesis with multiple functional readouts\",\n      \"pmids\": [\"29336889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GTP-bound K-Ras4B catalytic domain forms stable homodimers with two major dimer interfaces: a β-sheet interface overlapping switch I and effector-binding regions (inhibitory to effectors) and a helical interface that may promote Raf activation, suggesting Ras self-association regulates effector binding.\",\n      \"method\": \"Structural modeling, biophysical characterization of K-Ras4B GTP-bound catalytic domain dimerization\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structural/biophysical analysis with functional inference, single lab, no in-cell validation in this study\",\n      \"pmids\": [\"26051715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Full-length, natively processed K-Ras4B (with farnesylation and methylation) lacks intrinsic dimerization capability on supported lipid bilayer membranes across a wide range of surface densities and lipid compositions, suggesting any lateral organization in living cells requires additional factors.\",\n      \"method\": \"Fluorescence correlation spectroscopy and single-molecule tracking in supported lipid bilayer membranes\",\n      \"journal\": \"Biophysical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — rigorous biophysical in vitro assay with native post-translational modifications, single lab, directly contradicts some dimerization claims\",\n      \"pmids\": [\"29320680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"KRAS G13D mutant is sensitive to neurofibromin (NF1)-stimulated GTP hydrolysis. Crystal structures of KRAS G13D in complex with the NF1 RasGAP domain provide the structural basis for this hydrolysis, and KRAS G13D-mutated cells can respond to EGFR inhibitors in a neurofibromin-dependent manner.\",\n      \"method\": \"In vitro GTP hydrolysis assay, crystal structure determination of KRAS G13D/neurofibromin complex, cell-based EGFR inhibitor response assays with NF1 dependency\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus in vitro biochemical assay plus cell-based functional validation, multiple orthogonal methods in one study\",\n      \"pmids\": [\"31611389\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Oncogenic mutations at G12, G13, and Q61 in K-Ras4B impair GAP-assisted GTP hydrolysis by disrupting the R789 arginine finger / Q61 catalytic organization. G12C/G12D mutations additionally expose the bound nucleotide in the GDP state, facilitating GDP-to-GTP exchange. The mutations differentially drive an inactive-to-active conformational transition in the GTP-bound state.\",\n      \"method\": \"Molecular dynamics simulations (6.4 μs total) on wild-type and mutant K-Ras4B with and without GAP\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Moderate — computational simulation only, no experimental validation in this study\",\n      \"pmids\": [\"26902995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Crystal structures of four FTase ternary complexes with K-Ras4B peptide substrates reveal that the CAAX motif binds in extended conformation coordinating the active-site zinc ion, and the K-Ras4B polybasic region forms a type I β-turn along the rim of the hydrophobic cavity, providing the molecular basis for the high-affinity specificity of K-Ras4B for FTase.\",\n      \"method\": \"X-ray crystallography (2 Å resolution ternary complex structures)\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution crystal structures with multiple complexes providing direct structural basis for substrate specificity\",\n      \"pmids\": [\"10673434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"K-Ras4B processing (farnesylation) is highly resistant to FTI-277 (IC50 ~10 μM) but sensitive to the GGTase I inhibitor GGTI-286 (IC50 ~2 μM), demonstrating that K-Ras4B can undergo geranylgeranylation as an alternative prenylation when farnesylation is blocked, and that its oncogenic signaling (MAP kinase activation) is selectively disrupted by GGTase I inhibition.\",\n      \"method\": \"Cell-based prenylation processing assay, MAP kinase activation assay, CAAX peptidomimetic inhibitor treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based biochemical assays with isoform-selective inhibitors, single lab, multiple functional readouts\",\n      \"pmids\": [\"7592913\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The C-terminal hypervariable region (HVR) of K-Ras4B is responsible for its specific interaction with calmodulin. The HVR binds specifically to the C-terminal domain of Ca2+-loaded calmodulin with micromolar affinity, while the GTP-γ-S-loaded catalytic domain may interact with the N-terminal domain of calmodulin, providing nucleotide-dependent control of the interaction.\",\n      \"method\": \"NMR spectroscopy and isothermal titration calorimetry\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — two orthogonal biophysical methods (NMR + ITC), domain-mapping experiments, single lab\",\n      \"pmids\": [\"19583261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Calmodulin (CaM) inhibits K-Ras4B phosphorylation at Ser181 by PKC in vivo. PKC-mediated Ser181 phosphorylation decreases K-Ras4B susceptibility to p120GAP activity and is required for sustained ERK/AKT activation, cell proliferation, and oncogenic functions including focus formation and apoptosis resistance.\",\n      \"method\": \"Cell-based phosphorylation assays, non-phosphorylable K-Ras mutant (S181A), p120GAP activity assay, proliferation and focus formation assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — site-directed mutagenesis plus multiple cell-based functional assays, single lab\",\n      \"pmids\": [\"20802526\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Ca2+/calmodulin extracts K-Ras4B from negatively charged membranes in a nucleotide-independent manner, and the CaM/K-Ras4B complex does not bind membranes, demonstrating that CaM regulates K-Ras4B plasma membrane localization by sequestering it from the bilayer. This mechanism differs from PDEδ-mediated regulation.\",\n      \"method\": \"Fluorescence/FRET spectroscopy, FCS, and imaging in heterogeneous model biomembranes with GDP- and GTP-loaded K-Ras4B\",\n      \"journal\": \"Biophysical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple biophysical methods with model membranes, single lab, in vitro reconstitution\",\n      \"pmids\": [\"27410739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"K-Ras4B associates dynamically with the plasma membrane and undergoes rapidly reversible binding; using rapamycin-regulated heterodimerization, K-Ras4B or its targeting sequence alone can transfer from the plasma membrane to mitochondria within minutes, unlike multiply lipid-modified constructs anchored to the PM.\",\n      \"method\": \"Fluorescence microscopy, rapamycin-regulated protein heterodimerization, live cell imaging\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct live-cell imaging with rapamycin-regulated system, quantitative kinetics, single lab\",\n      \"pmids\": [\"16236799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BI-2852 binds with nanomolar affinity to the switch I/II pocket between switch I and II of KRAS (present in both active and inactive forms), blocking all GEF, GAP, and effector interactions with KRAS simultaneously, leading to inhibition of downstream signaling and antiproliferative effects in KRAS mutant cells.\",\n      \"method\": \"Structure-based drug design, biochemical binding assay, GEF/GAP/effector interaction assays, cell proliferation assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure-guided design, multiple biochemical interaction assays demonstrating simultaneous blockade, cell-based functional validation\",\n      \"pmids\": [\"31332011\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"KRAS is poorly translated relative to HRAS due to enrichment in rare codons. Converting rare to common codons increases KRas protein expression and tumorigenicity to mirror that of HRas, demonstrating that synonymous codon usage is a hardwired regulatory mechanism controlling KRas protein levels and oncogenic activity.\",\n      \"method\": \"Codon-optimized KRAS expression constructs, protein expression quantification, tumorigenicity assays\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct experimental manipulation of codon usage with functional readouts (protein level, tumorigenicity), single lab\",\n      \"pmids\": [\"23246410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"K-RAS4B localized to the plasma membrane via prenylation adopts an orientation in which the membrane occludes the effector-binding site when a small molecule (Cmpd2) simultaneously engages a shallow pocket on KRAS and associates with the lipid bilayer, thereby reducing RAF binding and impairing RAF activation.\",\n      \"method\": \"NMR spectroscopy of prenylated K-RAS4B in lipid bilayer, RAF binding assay, cell signaling assay\",\n      \"journal\": \"Cell chemical biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structural analysis with lipid bilayer plus functional RAF binding assay, single lab\",\n      \"pmids\": [\"30122370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Phosphorylation at Ser181 reduces K-Ras4B membrane binding affinity without fully preventing membrane binding or clustering, and phosphorylated K-Ras4B maintains tight association with its cytosolic shuttle protein PDEδ; cells receiving a non-hydrolyzable phosphoserine mimetic show decreased plasma membrane distribution compared to non-phosphorylable K-Ras4B.\",\n      \"method\": \"Chemically synthesized K-Ras4B bearing phosphate, farnesyl and methyl modifications, model biomembrane binding assays, cell microinjection\",\n      \"journal\": \"ACS chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — fully post-translationally modified protein reconstituted in vitro, multiple biophysical methods, cell-based validation with phosphoserine mimetic\",\n      \"pmids\": [\"28448716\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Recombinant K-Ras4B interacts with lipids and this interaction is mediated by its C-terminal hypervariable region, as demonstrated using phospholipid bilayer nanodiscs.\",\n      \"method\": \"Nanodisc reconstitution, NMR, protein purification\",\n      \"journal\": \"Protein expression and purification\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct biophysical reconstitution with nanodiscs, single lab, single method\",\n      \"pmids\": [\"20566322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Wild-type Kras2 functions as a tumor suppressor in lung tumorigenesis: heterozygous Kras2-deficient mice show increased susceptibility to chemically-induced lung tumors, wild-type Kras2 inhibits colony formation and tumor development by cells with activated Kras2, and an inverse correlation exists between wild-type Kras2 expression and ERK activity.\",\n      \"method\": \"Mouse tumor bioassay with Kras2-deficient mice, colony formation assay, tumor xenograft, ERK activity measurement\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple in vivo and in vitro models, genetic and biochemical readouts, independently validated in human tumors\",\n      \"pmids\": [\"11528387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Kras is the unique Ras family member required for B cell development: hematopoietic-specific deletion of Kras impairs early B cell development at the pre-B cell stage and late maturation, and Kras deficiency specifically impairs pre-BCR- and BCR-induced activation of the Raf-1/MEK/ERK pathway in pre-B and mature B cells.\",\n      \"method\": \"Conditional Kras knockout mice, bone marrow chimeras with B cell-specific Kras deletion, B cell development analysis, Raf-1/MEK/ERK pathway analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional KO with multiple developmental stage readouts and pathway analysis, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"26773157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"KRAS-dependent transcription in KRAS-mutant cancers is driven predominantly through the ERK MAPK cascade. ERK deregulates the anaphase-promoting complex/cyclosome (APC/C) and other cell cycle machinery components as key processes driving PDAC growth, revealed by integration of KRAS/ERK-dependent transcriptome with ERK-regulated phospho- and total proteome.\",\n      \"method\": \"Genome-scale loss-of-function, RNA-seq, phosphoproteomics, total proteomics in KRAS-mutant cancer lines and patient data\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multi-omic approach integrating transcriptomics and proteomics with direct genetic perturbation, validated in patient data\",\n      \"pmids\": [\"38843331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Allosteric communication in KRAS propagates particularly effectively across the central β-sheet, and multiple surface pockets are genetically validated as allosterically active, including a distal pocket in the C-terminal lobe. Allosteric mutations typically inhibit binding to all tested effectors but can also change binding specificity, revealing potential to tune pathway activation.\",\n      \"method\": \"Deep mutational scanning of >26,000 KRAS mutations measuring effects on folding and binding to six interaction partners; genetic interaction analysis in double mutants to infer >22,000 causal free energy changes\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — large-scale quantitative biophysical measurements at protein scale with functional validation, multiple interaction partners tested\",\n      \"pmids\": [\"38109937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Feedback reactivation of RAS-MAPK signaling upon KRASG12C inhibition is driven by upstream feedback activation of wild-type RAS (not by a shift of KRASG12C to GTP-bound state), and multiple receptor tyrosine kinases can drive this reactivation in a KRASG12C-independent manner.\",\n      \"method\": \"Biochemical assays distinguishing KRASG12C-GTP vs wild-type RAS-GTP, RTK perturbation experiments, cell signaling analysis in NSCLC and CRC models\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple mechanistic approaches distinguishing KRASG12C from wild-type RAS reactivation, single lab\",\n      \"pmids\": [\"35732135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The disordered HVR of K-Ras4B undergoes auto-inhibition by shielding the effector binding site in the GDP-bound state, with release upon GTP binding or certain oncogenic mutations; oncogenic mutations G12V/G12D modulate HVR-phospholipid binding specificity toward preferential interactions with phosphatidic acid.\",\n      \"method\": \"NMR spectroscopy, phospholipid binding specificity experiments with oncogenic K-Ras4B mutants\",\n      \"journal\": \"Current opinion in structural biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — NMR-based structural analysis with partial functional follow-up, single lab, some claims are proposed/model-based\",\n      \"pmids\": [\"26709496\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ASP3082, a KRASG12D-selective degrader, induces KRASG12D protein degradation via a lysosome-dependent (VHL-mediated) process with remarkable selectivity, as shown by a crystal structure of the drug-induced ternary complex KRASG12D/ASP3082/VHL, with tumor regression in KRASG12D xenografts.\",\n      \"method\": \"Crystal structure of ternary complex, in vitro degradation assay, xenograft tumor model\",\n      \"journal\": \"Communications chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure of ternary complex plus in vitro and in vivo functional validation, single lab, rigorous structural basis\",\n      \"pmids\": [\"40849515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SRC kinase drives multidrug resistance to KRASG12C inhibition by activating the transcription factor JUN, which drives ABCC1 (multidrug transporter) expression. A genome-wide CRISPR screen identified ABCC1 as a resistance mediator, and SRC inhibitors (dasatinib, bosutinib) synergize with the KRASG12C inhibitor MRTX849 by blocking SRC-dependent JUN activation.\",\n      \"method\": \"Genome-wide CRISPR screen, JUN/ABCC1 pathway analysis, SRC inhibitor combination assays in cell lines, organoids, and mouse models\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — unbiased genome-wide CRISPR screen followed by mechanistic pathway validation and in vivo confirmation, multiple model systems\",\n      \"pmids\": [\"39661665\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"K-Ras4B forms dimers in vitro, observable with fully processed (farnesylated, methylated) protein preparations, suggesting dimerization could be important for activity and membrane interactions.\",\n      \"method\": \"In vitro biochemical characterization of purified K-Ras4B lipoprotein\",\n      \"journal\": \"Protein expression and purification\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single in vitro observation, single method, not functionally validated\",\n      \"pmids\": [\"22569482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CAF-derived NRG1 activates cancer cell ERBB2 and ERBB3 receptor tyrosine kinases to support KRAS*-independent growth in PDAC. Genetic extinction or pharmacological inhibition of KRAS* upregulates ERBB2 and ERBB3 in cancer cells, prompting use of CAF-derived NRG1 as a survival factor; inhibition of ERBB2/3 or NRG1 abolished KRAS* bypass.\",\n      \"method\": \"Genetic depletion and pharmacological inhibition of KRAS*, ERBB2/3, and NRG1 in mouse and human PDAC models, co-culture experiments\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological perturbations in multiple model systems, single lab, clear mechanistic pathway\",\n      \"pmids\": [\"37775182\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"KRAS encodes a membrane-associated small GTPase that cycles between inactive GDP-bound and active GTP-bound states regulated by GEFs and GAPs; oncogenic mutations (G12, G13, Q61) impair GAP-stimulated GTP hydrolysis (with G13D retaining neurofibromin-sensitivity), driving constitutive activation of RAF/MEK/ERK and PI3K/AKT downstream signaling; K-Ras4B requires farnesylation and polybasic HVR for plasma membrane localization, undergoes dynamic membrane association regulated by calmodulin (which extracts it from the membrane) and PDEδ, is phosphorylated at Ser181 by PKC (antagonized by CaM) to reduce GAP sensitivity and modulate signaling, and can dimerize via the α4-α5 interface in a manner that influences MEK inhibitor sensitivity and oncogenic activity; its rare codon enrichment limits protein expression compared to HRAS, and KRAS-driven transcription operates predominantly through ERK to deregulate the APC/C and cell cycle machinery.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"KRAS encodes a membrane-associated small GTPase that cycles between inactive GDP-bound and active GTP-bound states to drive RAF/MEK/ERK signaling, with oncogenic activation occurring when mutations at G12, G13, and Q61 disrupt the GAP arginine finger/Q61 catalytic organization required for GTP hydrolysis [#4]. The catalytic mutants are not uniformly GAP-insensitive: KRAS G13D retains susceptibility to neurofibromin (NF1)-stimulated hydrolysis, and KRAS G13D cells respond to EGFR inhibitors in an NF1-dependent manner [#3]. Plasma membrane targeting of K-Ras4B depends on C-terminal processing — FTase recognizes the CAAX motif and adjacent polybasic region with high specificity [#5], though the protein can be alternatively geranylgeranylated when farnesylation is blocked, with oncogenic MAP kinase signaling sensitive to GGTase I inhibition [#6]. Membrane association is dynamic and reversible [#10] and is governed by the hypervariable region, which mediates lipid binding [#15], interacts with Ca2+-loaded calmodulin to extract K-Ras4B from the bilayer [#7, #9], and is phosphorylated at Ser181 by PKC (antagonized by calmodulin) to reduce p120GAP susceptibility, lower membrane affinity, and sustain ERK/AKT-driven proliferation and oncogenic function [#8, #14]. KRAS can self-associate through a dimer interface, and the dimerization-defective KRAS D154Q mutant abrogates oncogenic activity and MEK-inhibitor resistance, establishing dimerization as required for KRAS function [#0]. Deep mutational scanning maps allosteric communication across the central β-sheet and identifies surface pockets that tune effector binding [#19], and KRAS-dependent transcription in mutant cancers operates predominantly through ERK to deregulate the APC/C and cell cycle machinery driving PDAC growth [#18]. Counterbalancing its oncogenic role, wild-type Kras2 acts as a tumor suppressor that restrains ERK activity and inhibits tumors driven by activated Kras [#16], and Kras is uniquely required among Ras genes for pre-BCR/BCR-driven Raf-1/MEK/ERK signaling in B cell development [#17]. KRAS is therapeutically targeted by switch I/II-pocket inhibitors [#11], membrane-orientation-modulating compounds [#13], and a KRAS G12D-selective VHL-recruiting degrader [#22], but resistance arises through feedback reactivation of wild-type RAS via RTKs [#20], SRC–JUN-driven ABCC1 expression [#23], and CAF-derived NRG1 engagement of ERBB2/3 [#25].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established how K-Ras4B reaches the membrane and whether its prenylation could be pharmacologically intercepted, revealing it escapes FTase inhibition via alternative geranylgeranylation.\",\n      \"evidence\": \"Cell-based prenylation and MAP kinase activation assays with isoform-selective CAAX inhibitors\",\n      \"pmids\": [\"7592913\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not establish in vivo relevance of GGTase I targeting in tumors\", \"No structural basis for the differential inhibitor sensitivity\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Defined the structural basis for K-Ras4B's high-affinity recognition by farnesyltransferase, explaining CAAX and polybasic-region specificity.\",\n      \"evidence\": \"X-ray crystallography of four FTase/K-Ras4B peptide ternary complexes at 2 Å\",\n      \"pmids\": [\"10673434\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Peptide substrates rather than full-length protein\", \"Does not address alternative prenylation enzymes\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrated that wild-type Kras paradoxically acts as a tumor suppressor restraining ERK, reframing the gene as dual-function rather than purely oncogenic.\",\n      \"evidence\": \"Kras2-deficient mouse lung tumor bioassays, colony formation, xenograft, and ERK activity measurement\",\n      \"pmids\": [\"11528387\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of WT suppression of mutant Kras not resolved here\", \"Tissue specificity of the suppressor role unclear\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showed that K-Ras4B membrane binding is rapidly reversible rather than static, establishing dynamic membrane shuttling as a regulatory feature.\",\n      \"evidence\": \"Rapamycin-regulated heterodimerization and live-cell imaging of PM-to-mitochondria transfer\",\n      \"pmids\": [\"16236799\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological trigger for membrane release not defined\", \"Single-cell imaging without endogenous-level confirmation\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified calmodulin as a nucleotide-sensitive HVR-binding partner, providing a molecular handle for K-Ras4B regulation beyond GEFs/GAPs.\",\n      \"evidence\": \"NMR and ITC domain-mapping of HVR/calmodulin interaction\",\n      \"pmids\": [\"19583261\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular consequence of binding not tested in this study\", \"Affinity measured on isolated domains\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Connected PKC-mediated Ser181 phosphorylation (CaM-antagonized) to reduced GAP sensitivity and oncogenic output, defining a phospho-switch on the HVR.\",\n      \"evidence\": \"Cell-based phosphorylation and S181A mutant assays, p120GAP activity, proliferation and focus formation\",\n      \"pmids\": [\"20802526\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Quantitative stoichiometry of phosphorylation in tumors unknown\", \"Direct structural effect on GAP binding not shown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Confirmed that the HVR is the lipid-binding determinant, grounding membrane targeting in a defined region.\",\n      \"evidence\": \"Nanodisc reconstitution and NMR of recombinant K-Ras4B\",\n      \"pmids\": [\"20566322\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single method, no in-cell validation\", \"Lipid composition dependence not explored\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Revealed that synonymous rare-codon usage hardwires low KRAS protein levels, explaining the expression and tumorigenicity gap versus HRAS.\",\n      \"evidence\": \"Codon-optimized KRAS constructs with protein-level and tumorigenicity readouts\",\n      \"pmids\": [\"23246410\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Translational mechanism (tRNA availability vs elongation) not dissected\", \"Relevance to endogenous regulation in normal tissue unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Proposed nucleotide-gated self-association with distinct dimer interfaces controlling effector access, opening the question of whether KRAS dimerizes functionally.\",\n      \"evidence\": \"Structural modeling and biophysical characterization of GTP-bound K-Ras4B catalytic domain\",\n      \"pmids\": [\"26051715\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in-cell validation in this study\", \"Catalytic domain only, lacks membrane context\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Provided an atomistic account of how G12/G13/Q61 mutations impair GAP-assisted hydrolysis and bias the active conformation.\",\n      \"evidence\": \"Microsecond molecular dynamics simulations of wild-type and mutant K-Ras4B ± GAP\",\n      \"pmids\": [\"26902995\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Computational only, no experimental validation in this study\", \"Does not capture full-length membrane-bound dynamics\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed calmodulin physically extracts K-Ras4B from membranes nucleotide-independently, defining a sequestration mechanism distinct from PDEδ.\",\n      \"evidence\": \"FRET/FCS/imaging in model biomembranes with GDP/GTP-loaded K-Ras4B\",\n      \"pmids\": [\"27410739\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vitro model membranes only\", \"Quantitative contribution to cellular PM pool not established\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established a unique, non-redundant requirement for Kras in B cell development via pre-BCR/BCR-driven MAPK signaling.\",\n      \"evidence\": \"Conditional Kras knockout mice and bone marrow chimeras with developmental and pathway analysis\",\n      \"pmids\": [\"26773157\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why other Ras genes cannot compensate is unresolved\", \"Direct receptor-to-Kras coupling not biochemically mapped\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrated with fully modified protein that Ser181 phosphorylation lowers membrane affinity while preserving PDEδ binding, integrating phospho-regulation with the shuttle machinery.\",\n      \"evidence\": \"Chemically synthesized phospho/farnesyl/methyl K-Ras4B, model membrane assays, cell microinjection\",\n      \"pmids\": [\"28448716\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling consequences not quantified here\", \"Endogenous phosphorylation dynamics not measured\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Provided in vivo genetic proof that dimerization (D154Q-sensitive) is required for oncogenic KRAS activity and MEK-inhibitor resistance.\",\n      \"evidence\": \"Inducible KRAS LOH model, D154Q dimer-interface mutant, in vitro and in vivo tumor and MEKi assays\",\n      \"pmids\": [\"29336889\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and partner of dimerization in cells not fully defined\", \"Apparent tension with native-protein in vitro non-dimerization findings\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Rigorously tested intrinsic dimerization of natively processed K-Ras4B and found none on bilayers, implying cellular clustering needs accessory factors.\",\n      \"evidence\": \"FCS and single-molecule tracking of farnesylated/methylated K-Ras4B on supported lipid bilayers\",\n      \"pmids\": [\"29320680\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not exclude dimerization driven by cellular factors\", \"Single in vitro system\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed that membrane orientation can occlude the effector site, identifying a druggable mode where a compound pins KRAS to the bilayer to block RAF.\",\n      \"evidence\": \"NMR of prenylated K-RAS4B in lipid bilayer plus RAF binding and signaling assays\",\n      \"pmids\": [\"30122370\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single compound, single lab\", \"In-cell potency and selectivity limited\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Resolved that KRAS G13D remains neurofibromin-sensitive, structurally and functionally rationalizing EGFR-inhibitor responsiveness for this allele.\",\n      \"evidence\": \"In vitro hydrolysis, KRAS G13D/NF1 crystal structure, NF1-dependent EGFR inhibitor cell assays\",\n      \"pmids\": [\"31611389\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generalizability to other codon-13 alleles untested\", \"NF1 status dependence in patients not addressed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Validated the switch I/II pocket as a druggable site whose occupancy simultaneously blocks GEF, GAP, and effector engagement.\",\n      \"evidence\": \"Structure-based design of BI-2852 with binding, interaction-blockade, and proliferation assays\",\n      \"pmids\": [\"31332011\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Potency insufficient for clinical use\", \"Mutant selectivity not achieved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Distinguished the source of adaptive resistance to KRASG12C inhibition as feedback activation of wild-type RAS via RTKs rather than re-loading of mutant KRAS.\",\n      \"evidence\": \"Biochemical KRASG12C-GTP vs WT-RAS-GTP discrimination and RTK perturbation in NSCLC/CRC models\",\n      \"pmids\": [\"35732135\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of dominant upstream RTK varies by context\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Mapped genome-wide allosteric architecture of KRAS, identifying β-sheet-propagated communication and distal pockets that tune effector specificity.\",\n      \"evidence\": \"Deep mutational scanning of >26,000 variants against six partners with double-mutant free-energy inference\",\n      \"pmids\": [\"38109937\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Druggability of identified distal pockets not demonstrated\", \"Performed outside full membrane context\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified a stromal bypass route in which CAF-derived NRG1 sustains KRAS-independent growth through ERBB2/3 upon KRAS extinction.\",\n      \"evidence\": \"Genetic/pharmacological KRAS, ERBB2/3, NRG1 perturbation and co-culture in PDAC models\",\n      \"pmids\": [\"37775182\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Contribution relative to cell-intrinsic resistance unquantified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed KRAS-mutant transcriptional output runs predominantly through ERK to deregulate the APC/C and cell cycle, defining the proliferative effector program.\",\n      \"evidence\": \"Genome-scale loss-of-function with integrated RNA-seq, phospho- and total proteomics in KRAS-mutant lines and patient data\",\n      \"pmids\": [\"38843331\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcription factors linking ERK to APC/C not all defined\", \"Tissue scope beyond PDAC partial\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined an SRC–JUN–ABCC1 axis driving multidrug resistance to KRASG12C inhibition and a synergistic SRC-inhibitor combination strategy.\",\n      \"evidence\": \"Genome-wide CRISPR screen with pathway validation and SRC-inhibitor combinations across cells, organoids, and mice\",\n      \"pmids\": [\"39661665\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Clinical translatability of the combination untested here\", \"Whether axis generalizes to other KRAS alleles unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Delivered targeted KRASG12D protein degradation via a VHL-recruiting degrader, expanding KRAS therapeutics from inhibition to mutant-selective destruction.\",\n      \"evidence\": \"Ternary KRASG12D/ASP3082/VHL crystal structure, in vitro degradation, and xenograft regression\",\n      \"pmids\": [\"40849515\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Resistance mechanisms to degradation not yet characterized\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the in vitro non-dimerizing behavior of natively processed K-Ras4B is reconciled with the genetic requirement for dimerization in cells — i.e., what cellular factors organize KRAS lateral assembly — remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Accessory factors driving cellular dimerization unidentified\", \"Structural model of the cellular dimer in a membrane context missing\", \"Quantitative link between dimerization and effector activation incomplete\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003924\", \"supporting_discovery_ids\": [3, 4]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [15, 21]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [4, 18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [10, 13, 14]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [9, 14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [18, 20]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [23, 25]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"NF1\", \"CALM1\", \"PDE6D\", \"RAF1\", \"PRKC\", \"VHL\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}